Q224 Financial Results August 8, 2024 Forward-Looking Statements Statements included in this presentation that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: Gilead's ability to achieve its anticipated full ye ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File No. 0-19731 ` GILEAD SCIENCES, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 94-3047598 (State or Other Jurisd ...

GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2024 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 6% Year-Over-Year to $6.7 billion Biktarvy Sales Increased 8% Year-Over-Year to $3.2 billion Oncology Sales Increased 15% Year-Over-Year to $841 million Foster City, CA, August 8, 2024 - Gilead Sciences, Inc. (Nasdaq: GILD) announced today its second quarter 2024 results of operations. "Gilead has had another strong quarter with 6% year-over-year growth in our base business. This was driven by sales of ...

Biotech giant Gilead Sciences, Inc. (GILD) is scheduled to report second-quarter 2024 results on Aug 8, after market close.The Zacks Consensus Estimate for sales and earnings is pegged at $6.64 billion and $1.61 per share, respectively.Image Source: Zacks Investment ResearchEarnings Surprise HistoryGILD’s earnings missed estimates in two of the trailing four quarters and beat the same in the other two, delivering an average surprise of 3.20%.Image Source: Zacks Investment ResearchWhat Our Model PredictsOur ...

Gilead Sciences (GILD) closed the latest trading day at $76.49, indicating a +0.57% change from the previous session's end. The stock's change was more than the S&P 500's daily loss of 1.37%. Elsewhere, the Dow saw a downswing of 1.21%, while the tech-heavy Nasdaq depreciated by 2.3%.Coming into today, shares of the HIV and hepatitis C drugmaker had gained 14.22% in the past month. In that same time, the Medical sector gained 0.74%, while the S&P 500 gained 1.11%.Analysts and investors alike will be keeping ...

Lubo Ivanko/iStock Editorial via Getty Images Gilead Sciences (NASDAQ:GILD) has dropped 15% YTD substantially underperforming the market. We last discussed the company two months, discussing how it was turning itself around. The company was impacted by tough trial results from Trodelvy, another disappointment given the more than $20 billion acquisition of Immunomedics. Despite that, the company has the ability to utilize its assets to generate strong returns while supporting a >4% yield. Gilead Sciences ...

In the latest market close, Gilead Sciences (GILD) reached $72.41, with a -0.21% movement compared to the previous day. The stock fell short of the S&P 500, which registered a gain of 1.08% for the day. At the same time, the Dow added 0.32%, and the tech-heavy Nasdaq gained 1.58%.Prior to today's trading, shares of the HIV and hepatitis C drugmaker had gained 2.67% over the past month. This has outpaced the Medical sector's gain of 0.31% and the S&P 500's gain of 0.43% in that time.Analysts and investors al ...

When I think of biotech stocks, I imagine volatile share prices and plenty of red ink. I also think of big-time shareholder returns for the industry’s winners. However, looking through the Bloomberg Billionaires Index, I don’t see one biotech company in the top 100. They must come later. How are biotech stocks doing in 2024? The Nasdaq Biotechnology Index, a list of 215 biotech and pharmaceutical stocks, is doing okay, up nearly 8% year-to-date, but less than half the Nasdaq 100. The gap gets worse over fiv ...

These three dividend vehicles could provide reliable passive income.Dividend stocks can be dual-threat vehicles, offering investors the best of both worlds. Specifically, these equities can act as reliable passive income generators while simultaneously possessing the potential to increase your net worth through share-price appreciation.If you're interested in buying a handful of dividend stocks as part of a passive income strategy, consider investing $51,000 across these three attractive options: AT&T (T 1. ...

Gilead Sciences (GILD) closed the latest trading day at $71.64, indicating a +1.17% change from the previous session's end. This change outpaced the S&P 500's 0.64% gain on the day. Meanwhile, the Dow gained 1.85%, and the Nasdaq, a tech-heavy index, added 0.2%.Shares of the HIV and hepatitis C drugmaker have appreciated by 10.18% over the course of the past month, outperforming the Medical sector's gain of 0.71% and the S&P 500's gain of 3.82%.Analysts and investors alike will be keeping a close eye on the ...